Advanced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)

Uma Ramaswami

London, ENG, GB 
Advanced in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Uma Ramaswami practices in London, United Kingdom. Ms. Ramaswami is rated as an Advanced expert by MediFind in the treatment of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). Her top areas of expertise are Fabry Disease, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), and Gastrostomy.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles and participated in 2 clinical trials in the study of Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome).

Gender
Female

Locations

London, ENG, United Kingdom
Other Locations
Box 157, Hills Rd, Cambridge CB2 0QQ, Cambridge, ENG, United Kingdom
St Mary's Hospital, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 3 Less Clinical Trials

87 Total Publications

Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C.
Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C.
Journal: Neurology
Published: June 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ramaswami's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile